Cargando…
Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls
BACKGROUND: Duchenne muscular dystrophy (DMD) is a rare, X-linked, fatal, degenerative neuromuscular disease caused by DMD gene mutations. A relationship between exon skipping and dystrophin production in exon 51-amenable patients treated with eteplirsen (EXONDYS 51(®)) is established. Once-weekly e...
Autores principales: | Mendell, Jerry R., Khan, Navid, Sha, Nanshi, Eliopoulos, Helen, McDonald, Craig M., Goemans, Nathalie, Mercuri, Eugenio, Lowes, Linda P., Alfano, Lindsay N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385516/ https://www.ncbi.nlm.nih.gov/pubmed/33523015 http://dx.doi.org/10.3233/JND-200548 |
Ejemplares similares
-
Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019) -
Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
por: Alfano, Lindsay N., et al.
Publicado: (2019) -
Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial
por: McDonald, Craig M., et al.
Publicado: (2021) -
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2016) -
Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)